27.88
price down icon1.59%   -0.45
after-market Handel nachbörslich: 27.80 -0.08 -0.29%
loading

Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten

pulisher
05:11 AM

Capricorn Fund Managers Ltd Buys 247,000 Shares of Roivant Sciences Ltd. $ROIV - marketbeat.com

05:11 AM
pulisher
Apr 04, 2026

Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data UpdateSlideshow (NASDAQ:ROIV) 2026-04-04 - Seeking Alpha

Apr 04, 2026
pulisher
Apr 04, 2026

ROIV PE Ratio & Valuation, Is ROIV Overvalued - Intellectia AI

Apr 04, 2026
pulisher
Apr 04, 2026

ROIV | Roivant Sciences Ltd. Common Executive Compensation - Quiver Quantitative

Apr 04, 2026
pulisher
Apr 04, 2026

Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial UpdatesHas The Bull Case Changed? - simplywall.st

Apr 04, 2026
pulisher
Apr 03, 2026

Roivant Sciences Ltd. (ROIV) stock price, news, quote and history - Yahoo Finance UK

Apr 03, 2026
pulisher
Apr 03, 2026

Roivant Sciences Ltd. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo

Apr 03, 2026
pulisher
Apr 03, 2026

Should Brepocitinib’s New Trials and Batoclimab’s Setback Require Action From Roivant Sciences (ROIV) Investors? - Yahoo Finance

Apr 03, 2026
pulisher
Apr 02, 2026

Roivant (NASDAQ: ROIV) executive settles RSU taxes with shares - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP - Yahoo Finance

Apr 02, 2026
pulisher
Apr 02, 2026

Roivant Shrugs Off Batoclimab Phase III Failure in TED - Citeline News & Insights

Apr 02, 2026
pulisher
Apr 02, 2026

Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint - Yahoo Finance

Apr 02, 2026
pulisher
Apr 02, 2026

Roivant (Nasdaq: ROIV) shows $4.3B cash and mixed late-stage trial results - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Scarring hair-loss disease gets drug trial with no approved therapy - Stock Titan

Apr 02, 2026
pulisher
Apr 01, 2026

Roivant Sciences (ROIV) executive settles CVARs and RSUs into shares - Stock Titan

Apr 01, 2026
pulisher
Apr 01, 2026

Roivant Sciences Ltd. (ROIV) Stock Forecasts - Yahoo Finance

Apr 01, 2026
pulisher
Apr 01, 2026

(ROIV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Apr 01, 2026
pulisher
Mar 31, 2026

Movement Recap: Is Roivant Sciences Ltd forming a bullish divergence2026 Patterns & Long-Term Capital Growth Strategies - baoquankhu1.vn

Mar 31, 2026
pulisher
Mar 31, 2026

CEO Change: Is Roivant Sciences Ltd a potential multi bagger2026 Pullbacks & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Mar 31, 2026
pulisher
Mar 31, 2026

Volume Summary: Is Roivant Sciences Ltd stock risky to hold now2026 Retail & Community Consensus Stock Picks - baoquankhu1.vn

Mar 31, 2026
pulisher
Mar 31, 2026

250,468 Shares in Roivant Sciences Ltd. $ROIV Acquired by Exchange Traded Concepts LLC - marketbeat.com

Mar 31, 2026
pulisher
Mar 31, 2026

Roivant Sciences Insider Sold Shares Worth $1,921,500, According to a Recent SEC Filing - MarketScreener

Mar 31, 2026
pulisher
Mar 31, 2026

Roivant Sciences Ltd (ROIV) Stock Price Quote Today & Current Price Chart - Capital.com

Mar 31, 2026
pulisher
Mar 31, 2026

Roivant Sciences Ltd (ROIV) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com

Mar 31, 2026
pulisher
Mar 30, 2026

Roivant Sciences (NASDAQ: ROIV) director exercises 70K options, sells 70K shares - Stock Titan

Mar 30, 2026
pulisher
Mar 30, 2026

Aug Sentiment: Is Roivant Sciences Ltd backed by strong institutional buyingStock Surge & Free Growth Oriented Trading Recommendations - baoquankhu1.vn

Mar 30, 2026
pulisher
Mar 30, 2026

Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success - Sahm

Mar 30, 2026
pulisher
Mar 30, 2026

Cantor Fitzgerald reiterates Roivant Sciences stock rating By Investing.com - Investing.com India

Mar 30, 2026
pulisher
Mar 30, 2026

Gains Recap: Should I hold or sell Roivant Sciences Ltd nowMarket Weekly Review & AI Driven Stock Movement Reports - baoquankhu1.vn

Mar 30, 2026
pulisher
Mar 30, 2026

Sentiment Watch: Is Roivant Sciences Ltd a potential multi bagger2026 Decliners & High Accuracy Swing Entry Alerts - baoquankhu1.vn

Mar 30, 2026
pulisher
Mar 29, 2026

ROIV Technical Analysis & Stock Price Forecast - Intellectia AI

Mar 29, 2026
pulisher
Mar 29, 2026

Bernstein initiates coverage of Roivant Sciences Ltd. (ROIV) with an outperform rating - msn.com

Mar 29, 2026
pulisher
Mar 28, 2026

New England Journal of Medicine publishes positive phase 3 valor trial results of brepocitinib in dermatomyositis - marketscreener.com

Mar 28, 2026
pulisher
Mar 28, 2026

NEJM study: rare muscle-skin disease drug beat placebo in Phase 3 - Stock Titan

Mar 28, 2026
pulisher
Mar 28, 2026

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis - Sahm

Mar 28, 2026
pulisher
Mar 28, 2026

Aug Ideas: Whats the fair value of Roivant Sciences Ltd stockTrade Exit Report & Community Verified Watchlist Alerts - baoquankhu1.vn

Mar 28, 2026
pulisher
Mar 27, 2026

Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)? - simplywall.st

Mar 27, 2026
pulisher
Mar 27, 2026

Can Roivant Sciences Ltd sustain earnings growthEarnings Performance Report & AI Forecasted Stock Moves - baoquankhu1.vn

Mar 27, 2026
pulisher
Mar 27, 2026

Big Money Moves: Can Roivant Sciences Ltd sustain earnings growthProduct Launch & Weekly Watchlist for Hot Stocks - baoquankhu1.vn

Mar 27, 2026
pulisher
Mar 27, 2026

Vanguard realignment leads to separate reports for Roivant (ROIV) - Stock Titan

Mar 27, 2026
pulisher
Mar 25, 2026

Bernstein Initiates Coverage of Roivant Sciences Ltd. (ROIV) with an Outperform Rating - Insider Monkey

Mar 25, 2026
pulisher
Mar 24, 2026

Roivant Sciences (ROIV) CFO reports RSU tax-withholding of 1,546 shares - Stock Titan

Mar 24, 2026
pulisher
Mar 24, 2026

Assenagon Asset Management S.A. Purchases 6,877,348 Shares of Roivant Sciences Ltd. $ROIV - marketbeat.com

Mar 24, 2026
pulisher
Mar 24, 2026

12 Best UK Stocks to Buy According to Hedge Funds - Insider Monkey

Mar 24, 2026
pulisher
Mar 23, 2026

Roivant Sciences, Genevant, Arbutus, and Moderna Settle International Patent Litigation – Key Terms and Confidentiality Details - Minichart

Mar 23, 2026
pulisher
Mar 22, 2026

Roivant Sciences (ROIV) soars 19.4% as pipeline drugs progress - MSN

Mar 22, 2026
pulisher
Mar 22, 2026

Roivant secures FDA priority review for dermatomyositis treatment - MSN

Mar 22, 2026
pulisher
Mar 21, 2026

Risk Analysis: Is Roivant Sciences Ltd backed by strong institutional buyingBreakout Watch & High Conviction Investment Ideas - baoquankhu1.vn

Mar 21, 2026
pulisher
Mar 21, 2026

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Mar 21, 2026
pulisher
Mar 21, 2026

(ROIV) Risk Channels and Responsive Allocation - Stock Traders Daily

Mar 21, 2026
pulisher
Mar 20, 2026

Bernstein initiates Roivant Sciences stock with outperform rating By Investing.com - Investing.com Australia

Mar 20, 2026
pulisher
Mar 20, 2026

Bernstein initiates Roivant Sciences stock with outperform rating - Investing.com

Mar 20, 2026
pulisher
Mar 20, 2026

Sanford C. Bernstein Begins Coverage on Roivant Sciences (NASDAQ:ROIV) - MarketBeat

Mar 20, 2026
pulisher
Mar 20, 2026

Roivant Sciences Insider Sold Shares Worth $5,648,000, According to a Recent SEC Filing - marketscreener.com

Mar 20, 2026
pulisher
Mar 19, 2026

Roivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares - MarketBeat

Mar 19, 2026
pulisher
Mar 19, 2026

Roivant (NASDAQ: ROIV) president exercises 200K options and sells 200K shares - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

Trade Recap: What is the dividend yield of Roivant Sciences LtdShort Setup & AI Based Trade Execution Alerts - baoquankhu1.vn

Mar 19, 2026
$47.32
price down icon 2.57%
$48.77
price down icon 0.87%
$91.28
price up icon 0.11%
ONC ONC
$302.49
price down icon 2.67%
$163.81
price up icon 0.85%
Kapitalisierung:     |  Volumen (24h):